Abstract
The role of heparin as an anticoagulant is well defined; however, its role in tumorigenesis and tumor progression is not clear yet. Some studies have shown that anticoagulant treatment in cancer patients improve overall survival, however, recent clinical trials have not shown a survival benefit in cancer patients receiving heparin treatment. In our previous studies we have shown the inhibitory effects of heparin on Hepatocyte Growth Factor (HGF)-induced invasion and migration in hepatocellular carcinoma (HCC) cells. In this study, we showed the differential effects of heparin on the behaviors of HCC cells based on the presence or absence of HGF. In the absence of HGF, heparin activated HGF/c-Met signaling and promoted motility and invasion in HCC cells. Heparin treatment led to c-Met receptor dimerization and activated c-Met signaling in an HGF independent manner. Heparin-induced c-Met activation increased migration and invasion through ERK1/2, early growth response factor 1 (EGR1) and Matrix Metalloproteinases (MMP) axis. Interestingly, heparin modestly decreased the proliferation of HCC cells by inhibiting activatory phosphorylation of Akt. The inhibition of c-Met signaling reversed heparin-induced increase in motility and invasion and, proliferation inhibition. Our study provides a new perspective into the role of heparin on c-Met signaling in HCC.
Similar content being viewed by others
Abbreviations
- ANOVA:
-
Analysis of variance
- BCA:
-
Bicinchoninic acid
- DSs:
-
Dermatan sulfates
- DMEM:
-
Dulbecco’s modified eagle medium
- EGR1:
-
Early growth response factor 1
- ERK1/2:
-
Extracellular signal-regulated kinases
- FBS:
-
Fetal bovine serum
- GAG:
-
Glycosaminoglycan
- GPC3:
-
Glypican 3
- Gab1:
-
Grb2 associated binder 1
- Grb2:
-
Growth factor receptor-bound protein 2
- HSPGs:
-
Heparan sulfate proteoglycans
- HCC:
-
Hepatocellular carcinoma
- HGF:
-
Hepatocyte growth factor
- MMPs:
-
Matrix metalloproteinases
- MAPK:
-
Mitogen-activated protein kinase
- NFDM:
-
Nonfat dry milk
- PBS:
-
Phosphate buffer saline
- PI:
-
Propidium iodide
- PI3K:
-
Phosphoinositide-3 kinase
- PVDF:
-
Polyvinylidene fluoride
- SDS:
-
Sodium dodecyl sulphate
- SEM:
-
Standard error of the mean
- SRB:
-
Sulforhodamin b
- TCA:
-
Trichloroacetic acid
- TBST:
-
Tris buffered saline/Tween-20
References
Bozkaya G, Korhan P, Cokakli M, Erdal E, Sagol O, Karademir S, Korch C, Atabey N (2012) Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer 11:64. doi:10.1200/JCO.2008.19.1635
Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27:1667–1674. doi:10.1200/JCO.2008.19.1635
Cokakli M, Erdal E, Nart D, Yilmaz F, Sagol O, Kilic M, Karademir S, Atabey N (2009) Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer 2407:9–65. doi:10.1186/1471-2407-9-65
Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude G (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29–33. doi:10.1038/311029a0
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207–2214. doi:10.1158/1078-0432.CCR-08-1306
Firtina Karagonlar Z, Koc D, Iscan E, Erdal E, Atabey N (2016) Elevated HGF expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in HCC cells. Cancer Sci. doi:10.1111/cas.12891
Furlan A, Kherrouche Z, Montagne R, Copin MC, Tulasne D (2014) Thirty years of research on met receptor to move a biomarker from bench to bedside. Cancer Res 74:6737–6744. doi:10.1158/0008-5472.CAN-14-1932
Ganepola GA, Mazziotta RM, Weeresinghe D, Corner GA, Parish CJ, Chang DH, Tebbutt NC, Murone C, Ahmed N, Augenlicht LH, Mariadason JM (2010) Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors. Clin Exp Metastasis 1:1–9. doi:10.1007/s10585
Gao JJ, Inagaki Y, Xue X, Qu XJ, Tang W (2011) C-met: a potential therapeutic target for hepatocellular carcinoma. Drug Discov Ther 1:2–11
Garber K (2014) MET inhibitors start on road to recovery. Nat Rev Drug Discov 13:563–565. doi:10.1038/nrd4406
Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Goug J, Bandyopadhyay A, Hartmann G, Butler PJG (2003) Functional map and domain structure of MET, the product of the c-Met protooncogene and receptor for hepatocyte growth factor/scatter factor. PNAS 100:12039–12044
Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89–103. doi:10.1038/nrc3205
Giordano S, Columbano A (2014) Met as a therapeutic target in HCC: facts and hopes. J Hepatol 60:442–452. doi:10.1016/j.jhep.2013.09.009
Grant DS, Kleinman HK, Goldbergt ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P, Rosen EM (1993) Scatter factor induces blood vessel formation in vivo. PNAS 90:1937–1941
Holmes O, Pillozzi S, Deakin JA, Carafoli F, Kemp L, Butler PJG, Lyon M, Gherardi E (2007) Insights into the structure / function of hepatocyte growth factor / scatter factor from studies with individual domains. J Mol Biol 367:395–408
Jia Y, Zhang L, Li Y, Wang Y, Guo W, Cao L, Li Z (2006) Effects on proliferation and migration of the human colon carcinoma cell line SW620 by silencing of hepatocyte growth factor expression. Clin Oncol Cancer Res 7:277–283
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–1595
Kermorgant S, Zicha D, Parker PJ (2004) PKC controls HGF-dependent c-Met traffic, signaling and cell migration. EMBO J 23:3721–3734
Kong-Beltran M, Stamos J, Wickramasinghe D (2004) The Sema domain of met is necessary for receptor dimerization and activation. Cancer Cell 6:75–84
Korhan P, Erdal E, Atabey N (2014) MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-met. Biochem Biophys Res Commun 4:1304–1312. doi:10.1016/j.bbrc.2014.06.142
Kunter I, Erdal E, Nart D, Yılmaz F, Karademir S, Sagol O, Atabey N (2014) Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma. Oncol Rep 31:573–580. doi:10.3892/or.2013.2932
Lee JJX, Chan JC, Choo SP (2015) Clinical development of c-Met inhibition in hepatocellular carcinoma. Diseases 3:306–324. doi:10.3390/diseases3040306
Lever R, Page CP (2002) Novel drug development opportunities for heparin. Nat Rev Drug Discov 1:140–148. doi:10.1038/nrd724
Lim HC, Multhaupt HAB, Couchman JR (2015) Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells. Mol Cancer 27:1. doi:10.1186/s12943-014-0279-8
LIovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327. doi:10.1002/hep.22506
Liu C, Rangnekar VM, Adamson E, Mercola D (1998) Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther 5:3–28
Lyon M, Deakin JA, Gallagher JT (2002) The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor. J Biol Chem 277:1040–1046
Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ Jr, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J (2015) Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Sci Signal 360:rab6. doi:10.1126/scisignal.2005916
Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N (2012) Heparin inhibits hepatocyte growth factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One 7:e42717. doi:10.1371/journal.pone.0042717
Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9:314–326. doi:10.1038/nrclinonc.2012.71
Rimassa L, Porta C, Borbath I, Daniele B, Finn RS, Raoul JL, Schwartz LH, He AR, Trojan J, Peck-Radosavljevic M, Abbadessa G, Goldberg T, Santoro A, Bruix J (2014) Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing phase III clinical trial. Hepatic Oncol 2:181–188. doi:10.2217/hep.14.3
Rubin JS, Day RM, Breckenridge D, Atabey N, Taylor WG, Stahl SJ, Wingfield PT, Kaufman JD, Schwall R, Bottaro DP (2001) Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling. J Biol Chem 276:32977–32983
Sakai K, Aoki S, Matsumoto K (2015) Hepatocyte growth factor and met in drug discovery. J Biol Chem 157:271–284. doi:10.1093/jb/mvv027
Sanford D, Lazo-Langner A (2014) The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials: reply. J Thromb Haemost 12:1574–1575. doi:10.1111/jth.12666
Spek CA, Versteeg HH, Borensztajn KS (2015) Anticoagulant therapy of cancer patients: will patient selection increase overall survival? Thromb Haemost 114:530–536. doi:10.1160/TH15-02-0124
Spina A, De Pasquale V, Cerulo G, Cocchiaro P (2015) HGF/c-MET axis in tumor microenvironment and metastasis formation. Biomed 3:71–88. doi:10.3390/biomedicines3010071
Takeuchi A, Yamamoto Y, Munesue S, Harashima A, Watanabe T, Yonekura H, Yamamoto H, Tsuchiya H (2013) Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells. Cancer Sci 104:740–749. doi:10.1111/cas.12133
You H, Ding W, Dang H, Jiang Y, Rountree CB (2011) c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54:879–889. doi:10.1002/hep.24450
Zhong GX, Gong Y, Yu CJ, Wu SF, Ma QP, Wang Y, Ren J, Zhang XC, Yang WH, Zhu W (2015) Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism. Tumour Biol 36:4689–4697. doi:10.1007/s13277-015-3117-8
Zhou AX, Toylu A, Nallapalli RK, Nilsson G, Atabey N, Heldin CH, Borén J, Bergo MO, Akyürek LM (2011) Filamin a mediates HGF/c-Met signaling in tumor cell migration. Int J Cancer 128:839–846. doi:10.1002/ijc.25417
Acknowledgments
We thank Prof. Brian Carr for critically reading the manuscript and improving the English. This work was supported by The Scientific and Technological Research Council of Turkey (Project # 110S349).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to declare
Additional information
Evin Iscan and Aysim Gunes contributed equally to this work.
Rights and permissions
About this article
Cite this article
İşcan, E., Güneş, A., Korhan, P. et al. The regulatory role of heparin on c-Met signaling in hepatocellular carcinoma cells. J. Cell Commun. Signal. 11, 155–166 (2017). https://doi.org/10.1007/s12079-016-0368-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12079-016-0368-0